Chang Xiao-tong, Wang Zhen-hui, Du Xin, Dong Ming-gang, Hou Li-juan, Liu Jie, Wang Jian, Zhou Jian-guang
Department of Biochemistry, Hebei North University, Zhangjiakou 075029, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006 Apr;28(2):230-3.
To explore the effect of polymorphism in codon Ala54Thr of human intestinal fatty acid-binding protein gene (IFABP) on the therapeutic efficacy of fenofibrate.
Totally 147 patients with hyperlipidemia [72 men mean age: (56.2 +/- 8.63) years; 75 women mean age: (58.4 +/- 9.12) years] were enrolled. IFABP genotypes were detected by polymerase chain reaction, Hha I digestion, and sequencing. Four weeks before and after treatment, the levels of fasting serum total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein A I (apoA I) and apolipoprotein B (apoB) were detected with biochemical techniques.
The frequency of IFABP genotype was 0.47 for A/A, 0.37 for A/T, and 0.16 for T/T, and the allelic frequency was 0.65 for A and 0.35 for T. No significant different was found in lipid levels in every genotype before treatment (P > 0.05). After 4 weeks of treatment, the levels of TC, TG, LDL-C, and apoB significantly decreased (P < 00.01), and the levels of HDH-C and apoA I significantly increased (P < 0.01). The total therapeutic efficacy on A54A and A54T were 97% and 95%, respectively. In the patients with T54T genotype after treatment, no significant difference in lipids levels was found except TG (P < 0.05), and the total efficacy was only 38%. The total therapeutic efficacies of fenofibrate on A54A and A54T were higher than those of T54T, and there was significant different between A54A and T54T (P < 0.01).
The polymorphism of human IFABP gene in hyperlipidemia is related with the therapeutic efficacy of fenofibrate, and the T54T IFABP genotype may have strong negative effect on such efficacy.
探讨人肠脂肪酸结合蛋白基因（IFABP）密码子Ala54Thr多态性对非诺贝特治疗效果的影响。
共纳入147例高脂血症患者[72例男性，平均年龄：（56.2±8.63）岁；75例女性，平均年龄：（58.4±9.12）岁]。采用聚合酶链反应、Hha I酶切及测序法检测IFABP基因分型。治疗前后4周，采用生化技术检测空腹血清总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白A I（apoA I）和载脂蛋白B（apoB）水平。
IFABP基因分型频率为A/A 0.47、A/T 0.37、T/T 0.16，等位基因频率为A 0.65、T 0.35。治疗前各基因型血脂水平差异无统计学意义（P>0.05）。治疗4周后，TC、TG、LDL-C和apoB水平显著降低（P<0.01），HDH-C和apoA I水平显著升高（P<0.01）。A54A和A54T的总治疗有效率分别为97%和95%。治疗后T54T基因型患者除TG外，血脂水平差异无统计学意义（P<0.05），总有效率仅为38%。非诺贝特对A54A和A54T的总治疗有效率高于T54T，A54A与T54T之间差异有统计学意义（P<0.01）。
高脂血症患者中人类IFABP基因多态性与非诺贝特的治疗效果相关，T54T IFABP基因型可能对此疗效有较强的负面影响。
